SUBSCRIBE
SUBSCRIBE

Dana-Farber Cancer Institute

NEWS
Genetown
Stop, Rewind: the Scientists Slowing the Ageing Process, Dana-Farber Cancer Institute Study
January 26, 2011
 · 
1 min read
Genetown
Congestive Heart Failure Risk in Breast Cancer Higher With Bevacizumab, Dana-Farber Cancer Institute Study
January 6, 2011
 · 
1 min read
Genetown
More Signs Lung Cancer Screening Could Save Lives, Dana-Farber Cancer Institute Study
December 29, 2010
 · 
1 min read
Genetown
‘Smart Drug’ Shrinks Aggressive Sarcoma and Lung Cancer, Dana-Farber Cancer Institute Study
October 28, 2010
 · 
1 min read
Drug Development
ESMO: New Agent Active in Advanced Ovarian Cancer, Dana-Farber Cancer Institute Study
October 15, 2010
 · 
1 min read
Genetown
Vitamins’ Impact on Colon Cancer Minimal: Dana-Farber Cancer Institute Study
September 8, 2010
 · 
1 min read
Pharm Country
Immunotherapy Shows Benefit in Prostate Cancer, Dana-Farber Cancer Institute Study
July 29, 2010
 · 
1 min read
BioCapital
Dana-Farber Cancer Institute Study on GlaxoSmithKline’s Avandia Raises Hope For Safer Diabetes Drugs
July 22, 2010
 · 
1 min read
Genetown
Creation Of Self-Assembling Nanodevices That Move And Change Shape On Demand, Harvard University And Dana-Farber Cancer Institute Study
June 23, 2010
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 14, 2026
 · 
13 min read
Press Releases
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
April 20, 2026
 · 
6 min read
Press Releases
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
March 9, 2026
 · 
6 min read
Press Releases
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 4, 2026
 · 
13 min read
Press Releases
TAG1 Announces Strategic Collaboration to Advance Targeted Alpha Therapies
March 2, 2026
 · 
3 min read
Press Releases
CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
February 20, 2026
 · 
15 min read
Press Releases
4D Path Joins Phase II Clinical Trial to Advance Predictive Biomarkers in Bladder Cancer
January 23, 2026
 · 
4 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer
December 16, 2025
 · 
19 min read
Press Releases
ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
December 16, 2025
 · 
19 min read
Press Releases
Pierre Fabre Pharmaceuticals Announces Updated Phase 3 Tabelecleucel Data at American Society of Hematology Meeting in Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
December 8, 2025
 · 
7 min read
Load More